Coya Therapeutics (COYA) investor relations material

Investment highlights

• Focused pipeline targeting neurodegenerative diseases with COYA 302 and COYA 303, addressing ALS, FTD, Alzheimer's, and Parkinson's.

• Near-term ALS data readout expected Q1 2027; Phase 2 ALSTARS enrollment to complete in H2 2026.

• Clinical signals in ALS and FTD show stabilization or improvement in function and cognition.

• Nobel-recognized scientific foundation and strategic partnership with Dr. Reddy's, including up to $700M in milestones and equity investment.

• Cash position of $43.2M as of June 30, 2026, funding operations into 2H 2027.

Scientific and clinical approach

• Combination therapy using low-dose IL-2 with CTLA4-Ig or GLP-1 RA aims to restore Treg function and reduce neuroinflammation.

• Early clinical studies in ALS and FTD show disease stabilization and improved Treg function.

• Approach is supported by Nobel Prize-winning science and external validation.

• Combination therapy leverages well-established drugs with favorable safety profiles.

ALS program overview

• ALS is a rapidly fatal disease with high unmet need; current therapies offer only modest benefit.

• Investigator-initiated study of COYA 302 in ALS showed stable or improved ALSFRS-R scores over 48 weeks in most patients.

• Phase 2 ALSTARS study is ongoing, with topline data expected Q1 2027 and Fast Track Designation granted.

• Dr. Reddy's holds global rights (excluding Japan and LATAM) for ALS, with significant milestone and royalty potential.